Christos Sachpekidis

24PUBLICATIONS
9CO-AUTHORS
Instruments and techniquesPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyModelling and simulation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jun 12, 2026
Impact of scan duration and scatter correction on quantitative accuracy in Yttrium-90 PET/CT imaging using LAFOV and SAFOV systems: a phantom and clinical evaluation.

|May 26, 2026
Beyond target lesions: Prognostic value of longitudinal AI-derived whole-body [1⁸F]FDG PET/CT metrics in metastatic melanoma.

|Oct 01, 2025
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial.

Christos Sachpekidis, Marina Hajiyianni, Martin Grözinger

|Sep 06, 2025
Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study.

Christos Sachpekidis, Devayani Machiraju, Dimitrios Stefanos Strauss

|Nov 07, 2024
Enhancing the diagnostic capacity of [18F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study.

Philip Alexander Glemser, Martin Freitag, Balint Kovacs

|Mar 08, 2024
Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma.

Christos Sachpekidis, Olof Enqvist, Johannes Ulén

Pageof 4

Frequent Collaborators

1 joint publications

Antonia Dimitrakopoulou-Strauss

1 joint publications

Annette Kopp-Schneider

1 joint publications

Konstantinos G Zeimpekis

1 joint publications

Carola Bregenzer